Aldeyra Therapeutics is making strides in developing innovative treatments for both common and rare immune-mediated diseases. With two new drug applications (NDAs) accepted by the FDA, the company is poised to potentially launch two new therapies. These NDAs validate Aldeyra's novel platforms for treating inflammatory conditions.
Reproxalap for Dry Eye Disease
Reproxalap, Aldeyra's candidate for dry eye disease, has a PDUFA date set for November 23, 2023. The company is actively engaging in partnering discussions and preparing for internal commercialization. Clinical trials have demonstrated Reproxalap's rapid onset and broad activity in treating dry eye, with recent data showing a statistically significant improvement in visual acuity (p < 0.0001) in patients treated with Reproxalap compared to vehicle. This improvement represents approximately a 37% increase in visual acuity. Aldeyra estimates the addressable market for dry eye disease in the U.S. to be $23 billion.
ADX-2191 for Primary Vitreoretinal Lymphoma
The FDA has granted priority review to Aldeyra's NDA for ADX-2191 in the treatment of primary vitreoretinal lymphoma (ocular lymphoma), a rare and aggressive retinal cancer lacking approved therapies. The PDUFA date is June 21, 2023. The NDA is supported by over 30 years of published literature on methotrexate, the active ingredient in ADX-2191, and safety data from the Phase 3 GUARD trial in proliferative vitreoretinopathy. If approved, ADX-2191 could become the first FDA-approved drug for ocular lymphoma, which affects an estimated 300 to 600 patients annually in the United States, with a median survival of less than five years for newly diagnosed patients.
ADX-629: Oral RASP Modulator
Aldeyra is also advancing ADX-629, a first-in-class orally administered RASP (reactive aldehyde species) modulator, in Phase 2 clinical trials for multiple systemic indications. These include idiopathic nephrotic syndrome, Sjogren-Larsson syndrome, and atopic dermatitis. Top-line results from the Sjogren-Larsson syndrome trial and Part 1 of the atopic dermatitis and idiopathic nephrotic syndrome trials are expected in the second half of 2023. A Phase 2 trial in refractory or unexplained chronic cough is also underway, with top-line results anticipated in the first half of this year. Additionally, a Phase 2 trial in moderate alcohol-associated hepatitis is planned for 2023, building on positive results from a Phase 2 alcohol challenge trial where ADX-629 improved signs of alcohol intoxication.
Expanding the RASP Modulator Pipeline
Aldeyra is expanding its RASP modulator pipeline with ADX-246 and ADX-248. A Phase 1/2 clinical trial of orally administered ADX-246 for systemic immune-mediated diseases and intravitreally injected ADX-248 for geographic atrophy is planned for the second half of 2023 or early 2024.
Further Development of ADX-2191
ADX-2191 is also being developed for proliferative vitreoretinopathy and retinitis pigmentosa, both retinal diseases without FDA-approved therapies. A Type C Meeting with the FDA is planned for mid-2023 to discuss the completion of clinical development of ADX-2191 for the prevention of proliferative vitreoretinopathy. Top-line results from the Phase 2 clinical trial of ADX-2191 in patients with retinitis pigmentosa are expected in the first half of this year.
With a strong cash position of $174.3 million as of December 31, 2022, Aldeyra believes it is well-funded to execute its operating plan into the second half of 2024, including the potential commercialization of Reproxalap and ADX-2191.
